Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
; 36(3): 289-299, 2018 03.
Article
in En
| MEDLINE
| ID: mdl-29178025
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Technology Assessment, Biomedical
/
Cost-Benefit Analysis
/
Irinotecan
Type of study:
Clinical_trials
/
Guideline
/
Health_technology_assessment
/
Prognostic_studies
Aspects:
Patient_preference
Limits:
Humans
Language:
En
Journal:
Pharmacoeconomics
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2018
Document type:
Article
Affiliation country:
United kingdom
Country of publication:
New Zealand